ABIVAX Société Anonyme (FRA:2X1)
Germany · Delayed Price · Currency is EUR 77.40
+1.00 (1.31%)
Last updated: Oct 24, 2025, 8:01 AM CET
ABIVAX Société Anonyme Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 69 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | 2X1 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Marc M. de Garidel | Chief Executive Officer |
| Didier Blondel | Chief Financial Officer |
| Patrick Malloy | Head of Investor Relations |